Belrose relies on its collaborations to advance its development programs to address unmet clinical needs. We
Two of our clinical-stage assets were acquired in 2014 while two of these clinical-stage assets were acquired from publicly-traded Enzon Pharmaceuticals in 2013, as part of Belrose’s acquisition of Enzon’s PEGylation linker technologies.
Belrose leverages its proprietary technologies and proven expertise to provide services and research-stage clinical candidates to development partners.
Belrose currently has development partnerships with several companies interested in leveraging Belrose’s proprietary technology to develop new dosage forms and/or enhance their own pharmaceutical products and/or clinical candidates.
Academic & Research Collaborations
In addition to partnerships with private companies, Belrose Pharma has development and collaboration partnerships with the following academic and research institutions: